Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Meldonium - Grindeks

Drug Profile

Meldonium - Grindeks

Alternative Names: Kvaterin; MET-88; Mildronate; Quaterin

Latest Information Update: 04 Jul 2016

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Latvian Institute of Organic Synthesis
  • Developer Grindeks; Taiho Pharmaceutical
  • Class Adjuvants; Antiarrhythmics; Cardiotonics; Ischaemic heart disorder therapies; Methylhydrazines; Propionates; Small molecules; Vasodilators
  • Mechanism of Action Gamma-butyrobetaine dioxygenase inhibitors; Partial fatty acid oxidation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Heart failure; Ischaemic heart disorders
  • No development reported Angina pectoris; Arrhythmias

Most Recent Events

  • 04 Jul 2016 Phase III development is ongoing in China
  • 30 May 2014 Phase-III clinical trials in Heart failure in China (IV)
  • 30 May 2014 Phase-III clinical trials in Heart failure in China (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top